Khalid M. Darwish,
Salma A. Al-Ojaly,
- Faculty of Science, Department of Chemistry, University of Benghazi, Benghazi, Libya
- Student, Department of Chemistry, University of Benghazi, Benghazi, Libya
Abstract
This research reviews the role of anticancer organic compounds, focusing on Tamoxifen as a Selective Estrogen Receptor Modulator (SERM) and briefly comparing it to Vincristine and Vinblastine (Vinca alkaloids). At first, the review includes: classification of cancer stages, revealing symptoms of each stage. Moreover, the review gives an overview of the general classification of most of the cancer drugs, types of cancer drugs used specially in Libya, their structural differences and pharmacological mechanisms, their metabolism of action and pharmacokinetics, their manufacturing/extraction and methods of synthesis (descriptive/industrial level), an explanation of their effects on cells and tissues, their possible or probable side effects, and a guideline on monitoring the imported food products containing preservatives that may interact with cancer drugs or affect public health and concentrate on their expiry date, applying the legal action on any illegal performance. The research also focuses on cancer types of interest, with particular emphasis on the most prevalent types in Libya (such as breast, colon, lung cancer, colorectum and others). The research also gives an idea of the total number of all cancer patients in Libya and comparing it for both sexes till the year 2020 according to previously published articles by the National Cancer Control Program (NCCP) and National Cancer Registry.
Keywords: Anticancer drugs, Breast, Vinka Alkaloids, Tamoxifen, Colon, Lung
Khalid M. Darwish, Salma A. Al-Ojaly. Anti-Cancer Drugs-Common Types in Libya Tamoxifen: Structure and Synthesis. Research and Reviews: A Journal of Pharmaceutical Science. 2025; 17(01):-.
Khalid M. Darwish, Salma A. Al-Ojaly. Anti-Cancer Drugs-Common Types in Libya Tamoxifen: Structure and Synthesis. Research and Reviews: A Journal of Pharmaceutical Science. 2025; 17(01):-. Available from: https://journals.stmjournals.com/rrjops/article=2025/view=233567
References
1. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman & Gilman’s: The Pharmacological Basis of Therapeutics (13th Edition). McGraw-Hill Education.
2. National Cancer Institute. Cancer Staging. 2022. Accessed at https://www.cancer.gov/about-cancer/diagnosis-staging/staging on September 6, 2024.
3. S. Briest. Tamoxifen Metabolism and Its Effect on Endocrine Treatment of Breast Cancer, Clinical Advances in Hematology & Oncology, 2009, 7(3): 185-192.
4. Jordan, V. C. (2003). Tamoxifen: A Most Successful Targeted Therapy. Nature Reviews Drug Discovery, 2, 205–213.
5. Y. G. Kim, Y. H. Park, E. Y. Yang, W. S. Park, K. S. Park. Inhibition of tamoxifen’s therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines, Annals of Surgical Treatment and Research, 2019; 97(5):230-238.
6. Cragg, G. M., & Newman, D. J. (2005). Plants as a source of anti-cancer agents. Journal of Ethnopharmacology, 100(1–2), 72–79.
7. N. G. Coufal and L. Farnaes. (2011). The Vinca Alkaloids, In book: Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures (pp.25-37).
8. Weinberg, R. A. (2014). The Biology of Cancer (2nd Edition). Garland Science.
9. W. Krause. Resistance to anti-tubulin agents: From vinca alkaloids to epothilones, Cancer Drug Resist 2019;2:82-106.
10. FDA Drug Label: Tamoxifen (NDA 018181).
11. S. Lymch and E. M. Vivian. Drug Interactions, MSD Manual, 2025.
12. Xingyu Wang, Benoît Gigant, Xi Zheng, Qiang Chen. Microtubule-targeting agents for cancer treatment: Seven binding sites and three strategies. MedComm – Oncology, 2023, 2 (3), 1-20
13. Nisa Nur Iskandar and Iriawati. Vinblastine and Vincristine Production on Madagascar Periwinkle (Catharanthus roseus (L.) G. Don) Callus Culture Treated with Polethylene Glycol, Makara Journal of Science, 20/1 (2016), 7-16
14. PubChem Database – Vincristine. https://pubchem.ncbi.nlm.nih.gov/compound/Vincristine
15. PubChem Database – Vinblastine. https://pubchem.ncbi.nlm.nih.gov/compound/Vinblastine
16. Kimberly D. Miller, Leticia Nogueira, Theresa Devasia, Angela B. Mariotto, K. Robin Yabroff, Ahmedin Jemal, Joan Kramer and Rebecca L. Siegel. Cancer treatment and survivorship statistics, CA: a Cancer Journal for Clinicians, 2022, 72(5): 409-436q
17. I. Shiina, Y. Sano, K. Nakata, M. Suzuki, T. Yokoyama, A. Sasaki, T. Orikasa, T. Miyamoto, M, Ikekita, Y. Nagahara, and Y. Hasome. An expeditious synthesis of tamoxifen, a representative SERM (selective estrogen receptor modulator), via the three-component coupling reaction among aromatic aldehyde, cinnamyl trimethyl silane, and β-chlorophenetole, Bioorganic & Medicinal Chemistry, 2007, 15(24): 7599-7617.
18. N. Houssein. Cancer incidence in Libya using estimates from GLOBOCAN 2020. Series Clin Med Case Rep Rev. 2024;2(4):1-5.
19. The Global Cancer Observatory (GCO). Population fact sheets. 2020. Accessed. Dec 2023.
20. R. Tandon, V. Luxami, N. Tandon, and K. Paul. Recent advances in the synthesis of tamoxifen and analogues in medicinal chemistry, Asian Journal of Organic Chemistry, 2016, 10, 1-35.
21. Heijnen D., et al., “An atom efficient synthesis of tamoxifen”, Organic & Biomolecular Chemistry, 2019.
22. Itami K., et al., “Diversity-Oriented Synthesis of Tamoxifen-type compounds”, Journal of the American Chemical Society, 2003.
23. Patent EP0126470A1, “Process for the preparation of tamoxifen”, European Patent Office.
24. Tandon N., & Tandon R., “Synthesis of Tamoxifen derivatives and their biological activities”, Plant Archives, 2021.
25. J-A R-Méndez, R Ri-Castellanos, J-F S-Cruz, R. E. M-Puc. Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos, Transl Cancer Res 2019;8(1):23-34
Research and Reviews: A Journal of Pharmaceutical Science
| Volume | 17 |
| 01 | |
| Received | 24/11/2025 |
| Accepted | 04/12/2025 |
| Published | 06/12/2025 |
| Publication Time | 12 Days |
Login
PlumX Metrics